Clinical trial
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With…
NCT00424463 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00424463 |
|---|---|
| Title | Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| Official title | An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) |
| Intervention type | Drug |
| Interventions | MCI-186, Placebo of MCI-186 |
| Enrollment | 181 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jan 19, 2007 |
| Last update posted | Jan 6, 2026 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: